Radioactive drug trial aims at rare eye cancer

NCT ID NCT05496686

Ongoing Disease control Sponsor: Modulation Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests a radioactive drug called 225Ac-MTI-201 in 16 people with metastatic uveal melanoma, a rare eye cancer that has spread to other parts of the body. The main goal is to find the highest safe dose and understand side effects. Participants receive a single IV dose, and researchers monitor for toxicities and how the drug leaves the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 225Ac-MTI-201 (a radioactive drug given by IV)
What this could lead to: If it works, this could point toward a new treatment option for metastatic uveal melanoma, a rare eye cancer that has spread.
What could go wrong: This is a very early, small Phase 1 trial with only 16 people. The main goal is safety, not effectiveness. The radioactive drug may cause serious side effects, and it is unknown if it will shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic neoplasm Neoplasm Metastasis uveal melanoma Uveal Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC UVEAL MELANOMA

Contacts and locations

Locations

H. Lee Moffitt Cancer Center and Research Institute

Tampa, Florida, 33612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.